Eli Lilly and Co. Seek Emergency FDA Approval for Experimental Antibody Therapy for COVID-19
THURSDAY, Oct. 8, 2020 — Eli Lilly and Co. is seeking U.S. approval for emergency use of an experimental antibody therapy for COVID-19.
The request to the U.S. Food and Drug Administration is based on partial clinical trial findings suggesting the drug reduced symptoms, the amount of virus, hospitalizations and ER visits for patients with mild or moderate COVID-19, the Associated Press reported.
The results were released Wednesday in a news release, and they haven’t been published or reviewed by independent researchers.
The FDA granted emergency approval for the antiviral drug remdesivir, but it’s not clear if there’s enough evidence for Lilly’s antibody therapy to be approved, the AP reported.
Copyright © 2019 HealthDay. All rights reserved.